Category Archives: Cancer Therapies

Oncotarget Gives Great News to those with PTC

The nationally peer-reviewed journal Oncotarget is responsible for the resurgence of research on the pathological effects of cancer treatment and cancer diagnosis. Oncotarget firmly and rightly believes that the more hope a patient feels when going through the battle of cancer the greater chance they will survive the ordeal. They have found that many factors contribute to an overall feeling of hope including things to look forward to in the future, family support systems, and religious observance.

Oncotarget routinely examines various programs that manage cancer and pain to review them based on their ability to increase a patient’s quality of life. Check the journal at SCImago Journal & Country Rank.

Oncotarget recently sat down with Dr. Carmelo Nucero to interview him on his breakthrough research concerning papillary thyroid carcinoma. For those who may not know, papillary thyroid carcinoma has long been known to oncologists as the “resistant cancer.” This is due to its ability to develop a resistance to vemurafenib which targets the BRAF gene which is the cause of papillary thyroid carcinoma. This has led to many patients watching as their cancer goes into remission only to be called back into the oncologist office to be told that their cancer is now drug-resistant and incurable.

Dr. Carmelo Nucero was tired of being unable to give them the hope they desired, so he began taking many years to research how to make papillary thyroid carcinoma less resistant to the drug vemurafenib. He was able to find that when vemurafenib was mixed with palbociclib that both drugs became more effective.

What would happen is that the body would begin recognizing vemurafenib as a domestic substance. Once that occurred the two drugs were able to work in harmony and palbociclib promoted stronger cell regeneration of healthy cells while vemurafenib was able to promote more cell elimination for the cancer cells. Learn more about Oncotarget at Eurekalert.org.

Dr. Carmelo Nucero says that the FDA seems favorable the passage treatment since both drugs have Artie been approved previously.

To stay up-to-date on the news regarding Dr. Carmelo Nucero’s research and much more, subscribe to Oncotarget’s podcast which is available on iTunes and the Google play store.

Follow: https://twitter.com/oncotargetjrnl?lang=en

Just Who Is Dr. Clay Siegall

There are some truly great individuals who have graced us with their presence throughout history. unfortunately, many of these individuals never seem to get introduced into our households. The perfect example of this notion comes in the form of a man named Clay Siegall. Siegall is a scientist, a doctor, a philanthropist and an author. The guy has written up to 70 successful publications, and he’s the current holder of at least 15 patents. Clay Siegall is the CEO, Founder and President of the nation’s largest biotech company. Seattle Genetics is its name and fighting cancer is its game.

This company is located in Bothell, Washington, and it has revolutionized the industry with its cancer fighting medications. These medications are some of the most innovative drugs on the market today. Antibody-Based Therapies deliver a cell killing blow to cancer cells within the body. These medications attacks the cells and destroys them with little-to-no side effects. Unlike chemotherapy and other cancer fighting medications, these advanced therapies decreases the ill effects, which can make the patient feel even sicker. Siegall is the man in charge of it all, and he has helped the company to excel by obtaining multiple strategic licenses for distribution. This distribution allow the medications to be used in other countries. As of today, the medications are being used in 65 countries.

Dr. Siegall has used his brilliant way of thinking, his knowledge, and his expertise to secure this deal and with many more drugs in the pipeline, Seattle Genetics will continue to grow. Siegall posts the updated information on his blog. This blog is used to discuss what’s going on in the cancer research society as well as other interesting topics. One of his latest posts was for the criticism of the Paris Climate Agreement. Siegall also spoke on random topics such as science and politics.

Thanks to his profound interest in saving lives, Siegall has become the “go to” guy for research. Who knows what the future may hold, but the fight against cancer has made much more progress than eras of the past.